EU-PEARL brings platform trials to the limelight to mark World Mental Health Day

EU-PEARL is advancing patient-centric collaborative platform trials to accelerate the development of medicines. These type of trials trials efficiently assess different investigational treatments within a single disease simultaneously, sequentially, and in an adaptive manner. They can potentially shorten the timeline to develop and bring to market new medicines for patients. One of the disease areas, EU-PEARL focuses on is Major Depressive Disorder (MDD).

One of the disease areas, EU-PEARL focuses on is Major Depressive Disorder (MDD).

To mark World Mental Health Day (WMHD) on 10th October, Estefanía Cordero (EPF) spoke to Professor Carmine Pariante (KCL) and Fanni-Laura Mäntylä, patient advocate and member of EU-PEARL’s Patient Advisory Board to discuss their work in this IMI project. In this thought-provoking podcast, they reflect on mental health in the COVID aftermath and discuss research priorities. They also offer a glimpse on the role played by patients’ representatives in this project to ensure that future platform trials in any disease area, are truly patient centric.  

Listen to the podcast here.

Learn more about platform trials.